PubRank

Elizabeth R Unger

Author PubWeight™ 163.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 13.20
2 Prevalence of HPV infection among females in the United States. JAMA 2007 10.55
3 Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013 6.04
4 Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 2003 4.93
5 Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014 4.50
6 Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003 4.46
7 Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002 3.42
8 Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008 2.98
9 Chronic fatigue syndrome--a clinically empirical approach to its definition and study. BMC Med 2005 2.97
10 Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011 2.88
11 Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015 2.73
12 Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009 2.43
13 Psychometric properties of the CDC Symptom Inventory for assessment of chronic fatigue syndrome. Popul Health Metr 2005 1.94
14 A population-based study of the clinical course of chronic fatigue syndrome. Health Qual Life Outcomes 2003 1.80
15 The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med 2005 1.78
16 Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology. J Clin Microbiol 2006 1.75
17 Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005 1.67
18 Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2011 1.64
19 Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty. Cancer 2013 1.64
20 Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 2007 1.60
21 Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 2005 1.51
22 Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2003 1.39
23 Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. Arch Gen Psychiatry 2006 1.31
24 Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis 2012 1.26
25 Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010 1.24
26 Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011 1.21
27 Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers 2002 1.20
28 A real-time PCR assay for HPV52 detection and viral load quantification. Clin Lab 2012 1.18
29 DNA and RNA references for qRT-PCR assays in exfoliated cervical cells. J Mol Diagn 2006 1.15
30 Primary and secondary prevention of cervical cancer--opportunities and challenges. J Natl Cancer Inst 2009 1.13
31 Human papillomavirus and molecular considerations for cancer risk. Cancer 2008 1.12
32 Factor analysis of symptoms among subjects with unexplained chronic fatigue: what can we learn about chronic fatigue syndrome? J Psychosom Res 2004 1.12
33 Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013 1.12
34 Human papillomavirus genotypes in high-grade cervical lesions in the United States. J Infect Dis 2012 1.12
35 Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? J Infect Dis 2011 1.11
36 Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome. J Transl Med 2003 1.10
37 Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with chronic fatigue syndrome. Psychosom Med 2008 1.06
38 Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 2005 1.06
39 Sensitive and specific peak detection for SELDI-TOF mass spectrometry using a wavelet/neural-network based approach. PLoS One 2012 1.06
40 Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study. BMC Neurol 2006 1.05
41 Assessing the relationship between HIV infection and cervical cancer in Côte d'Ivoire: a case-control study. BMC Infect Dis 2010 1.05
42 CDC grand rounds: Reducing the burden of HPV-associated cancer and disease. MMWR Morb Mortal Wkly Rep 2014 1.05
43 Identifying illness parameters in fatiguing syndromes using classical projection methods. Pharmacogenomics 2006 1.05
44 Type-specific reproducibility of the Roche linear array HPV genotyping test. J Clin Virol 2008 1.04
45 Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 2014 1.04
46 Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev 2004 1.04
47 Gene expression correlates of unexplained fatigue. Pharmacogenomics 2006 1.03
48 Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012 1.03
49 Evaluation of the rapid BioStar optical immunoassay for detection of Chlamydia trachomatis in adolescent women. J Clin Microbiol 2008 1.03
50 Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. J Virol Methods 2006 1.02
51 Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis 2013 1.02
52 National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003 1.02
53 Performance of commercial reverse line blot assays for human papillomavirus genotyping. J Clin Microbiol 2012 1.01
54 Human papillomavirus type 16 E2 and E6/E7 variants. Gynecol Oncol 2005 1.00
55 Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 2013 0.99
56 Regional distribution of fatiguing illnesses in the United States: a pilot study. Popul Health Metr 2004 0.98
57 Minimum data elements for research reports on CFS. Brain Behav Immun 2012 0.96
58 Impact of RNA extraction from limited samples on microarray results. Biotechniques 2003 0.95
59 Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. Neuromolecular Med 2010 0.94
60 Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis 2014 0.94
61 Coping styles in people with chronic fatigue syndrome identified from the general population of Wichita, KS. J Psychosom Res 2006 0.94
62 Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening. J Womens Health (Larchmt) 2013 0.93
63 Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome. J Mol Med (Berl) 2004 0.93
64 Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol 2005 0.92
65 Gene expression profile of cervical tissue compared to exfoliated cells: impact on biomarker discovery. BMC Genomics 2005 0.92
66 Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer Causes Control 2014 0.92
67 Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol 2014 0.91
68 Exploration of neuroendocrine and immune gene expression in peripheral blood mononuclear cells. Brain Res Mol Brain Res 2004 0.91
69 Assessment of normal variability in peripheral blood gene expression. Dis Markers 2002 0.91
70 Effect of storage temperatures on the stability of cytokines in cervical mucous. Cytokine 2007 0.91
71 Short duration of elevated vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. J Virol 2004 0.90
72 The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 2011 0.89
73 Bioelectronic DNA detection of human papillomaviruses using eSensor: a model system for detection of multiple pathogens. BMC Infect Dis 2003 0.88
74 Characterization of the Human Cervical Mucous Proteome. Clin Proteomics 2010 0.88
75 Optimization of SELDI-TOF protein profiling for analysis of cervical mucous. J Proteomics 2008 0.88
76 Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991--1994. Sex Transm Dis 2008 0.87
77 Implementation of exon arrays: alternative splicing during T-cell proliferation as determined by whole genome analysis. BMC Genomics 2010 0.87
78 Oral sampling and human papillomavirus genotyping in HIV-infected patients. J Oral Pathol Med 2011 0.87
79 Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA. BMC Res Notes 2011 0.87
80 Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine 2013 0.87
81 Perception versus polysomnographic assessment of sleep in CFS and non-fatigued control subjects: results from a population-based study. BMC Neurol 2007 0.87
82 HPV prevalence among women from Appalachia: results from the CARE project. PLoS One 2013 0.86
83 Multiscale analysis of heart rate variability in non-stationary environments. Front Physiol 2013 0.86
84 Multicenter study of nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in children being evaluated for sexual abuse. Pediatr Infect Dis J 2009 0.85
85 Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2006 0.85
86 Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods 2012 0.85
87 Age-group differences in human papillomavirus types and cofactors for cervical intraepithelial neoplasia 3 among women referred to colposcopy. Cancer Epidemiol Biomarkers Prev 2011 0.85
88 Genital human papillomaviruses among women of reproductive age in Jamaica. Rev Panam Salud Publica 2013 0.84
89 HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PLoS One 2012 0.84
90 An evaluation of exclusionary medical/psychiatric conditions in the definition of chronic fatigue syndrome. BMC Med 2009 0.83
91 Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome. Neuropsychobiology 2011 0.83
92 Human papillomavirus type 16 variant assignment by pyrosequencing. J Virol Methods 2006 0.83
93 Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. Emerg Infect Dis 2015 0.83
94 International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine 2011 0.83
95 Evaluation of RNA markers for early detection of cervical neoplasia in exfoliated cervical cells. Cancer Epidemiol Biomarkers Prev 2007 0.82
96 Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Clin Vaccine Immunol 2012 0.81
97 Analysis of 16S rRNA gene sequences and circulating cell-free DNA from plasma of chronic fatigue syndrome and non-fatigued subjects. BMC Microbiol 2002 0.81
98 Exploration of statistical dependence between illness parameters using the entropy correlation coefficient. Pharmacogenomics 2006 0.81
99 Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study. Gynecol Oncol 2005 0.81
100 Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommon. J Gen Virol 2010 0.81
101 Gene expression profiling of dysplastic differentiation in cervical epithelial cells harboring human papillomavirus 16. Genomics 2005 0.80
102 Global amplification of sense RNA: a novel method to replicate and archive mRNA for gene expression analysis. Genomics 2003 0.80
103 The association of current hormonal contraceptive use with type-specific HPV detection. Sex Transm Infect 2011 0.79
104 Can clinical tests help monitor human papillomavirus vaccine impact? Int J Cancer 2013 0.79
105 Toward using National Cancer Surveillance data for preventing and controlling cervical and other human papillomavirus-associated cancers in the US. Cancer 2008 0.79
106 Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control 2013 0.78
107 Effect of specimen order on Chlamydia trachomatis and Neisseria gonorrhoeae test performance and adequacy of Papanicolaou smear. J Pediatr Adolesc Gynecol 2006 0.77
108 Evaluation of genital self-sampling methods for HPV detection in males. J Clin Virol 2013 0.77
109 HPV genotypes detected in cervical cancers from Alaska Native women, 1980-2007. Int J Circumpolar Health 2013 0.77
110 Human papillomavirus in amniotic fluid. BMC Pregnancy Childbirth 2006 0.76
111 Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev 2004 0.76
112 Early menopause and other gynecologic risk indicators for chronic fatigue syndrome in women. Menopause 2015 0.76
113 A pilot registry of unexplained fatiguing illnesses and chronic fatigue syndrome. BMC Res Notes 2013 0.75
114 Evaluation of the Vulvar Cancer Histology Code Reported by Central Cancer Registries: Importance in Epidemiology. Arch Pathol Lab Med 2016 0.75
115 Reply to Groner et al and Pei et al. J Infect Dis 2013 0.75
116 Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients. J Clin Virol 2011 0.75
117 Molecular characterization of human papillomaviruses by PCR and in situ hybridization. Methods Mol Med 2004 0.75
118 Modifying differential display polymerase chain reaction to detect relative changes in gene expression profiles. Anal Biochem 2002 0.75
119 Predictors of remission in juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003 0.75
120 Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014. NCHS Data Brief 2017 0.75
121 TPrevalence of HPV in Adults Aged 18-69: United States, 2011-2014. NCHS Data Brief 2017 0.75
122 Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005. Sex Transm Dis 2014 0.75
123 CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide. Emerg Infect Dis 2017 0.75
124 Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. Am J Epidemiol 2017 0.75
125 The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy. Am J Obstet Gynecol 2003 0.75
126 Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006. Sex Transm Dis 2016 0.75
127 CDC Grand Rounds: Chronic Fatigue Syndrome - Advancing Research and Clinical Education. MMWR Morb Mortal Wkly Rep 2016 0.75
128 Comparing Human Papillomavirus Prevalence in Rectal and Anal Cancer Using US Cancer Registries, 2014-2015. J Registry Manag 2019 0.75